Massachusetts Gov. Deval Patrick, the Massachusetts Life Sciences Center and seven global biopharmaceutical companies announced on Wednesday the formation of the Massachusetts Neuroscience Consortium. The announcement took place in the Massachusetts Pavilion at the 2012 BIO International Convention. Speakers included Patrick; Susan Windham-Bannister, president & CEO of the Massachusetts Life Sciences Center; James Hoyes, president, EMD Serono; Jeffrey Flier, Dean of Harvard Medical School; and patients.
The Consortium is a new model designed to leverage the rich biomedical environment in Massachusetts in order to accelerate early-stage research available to the pharmaceutical industry, introducing academic researchers to the challenges of targeted research, and facilitating industry-academic collaborations.
"The academic research community is committed to understanding these neurologic conditions at the most basic and fundamental molecular level, and most importantly, to translating that depth of understanding into clinical applications," said Flier. "Basic discovery and translational science are essential to our success, and we in academic have the infrastructure to do it."
Participating companies have each pledged $250,000 to the Consoritum, for total initial funding of $1.75 million.